1. Home
  2. Live Updates
  3. Ulcrum therapeutics

Live Breaking News & Updates on Ulcrum therapeutics

Stay informed with the latest breaking news from Ulcrum therapeutics on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ulcrum therapeutics and stay connected to the pulse of your community

Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights

Company's cash runway extended into 2026, with a net loss of $24.0 million for Q3 2023

Alexc-sapir , Fulcrum-therapeutics-inc , Iopharmaceutical-company , Ulc , Ickle-cell-disease , Ash-equivalents , Acioscapulohumeral-muscular-dystrophy , Ulcrum-therapeutics , 3-2022 , Linical-development , Ash-position

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq

CAMBRIDGE, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Cambridge , Cambridgeshire , United-kingdom , Chris-calabrese , Fulcrum-therapeutics-inc , Nasdaq , Linkedin , Lifesci-advisors , Stock-incentive-plan , Nasdaq-listing-rule , Sci-advisors , Nasdaq-fulc

Fulcrum Therapeutics Stock Rises 46% On FDA Lifting Clinical Hold

Shares of Fulcrum Therapeutics, Inc. (FULC) are rising 46.43 percent on Tuesday after it announced that the U.S. Food and Drug Administration or FDA has lifted the clinical hold on its Investigational New Drug (IND) application for FTX-6058, a drug for sickle-cell disease or SCD treatment.

Fulcrum-therapeutics-inc , Drug-administration , Fulcrum-therapeutics , Investigational-new-drug , Fda , Ulcrum-therapeutics , Tock-rises-46- , Ifting-clinical-hold ,

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq

CAMBRIDGE, Mass., July 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Cambridge , Cambridgeshire , United-kingdom , Dee-smith , Nasdaq , Fulcrum-therapeutics-inc , Corporate-communications , Drug-administration , Stock-incentive-plan , Fulcrum-therapeutics , Nasdaq-listing-rule , Nasdaq-fulc

FULC FINAL DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL,

NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum...

China , New-york , United-states , Chinese , Laurence-rosen , Phillip-kim , Facebook , Nasdaq , Drug-administration , Twitter , Rosen-law-firm , Securities-class-action-services

Fulcrum Therapeutics, Inc. (FULC) Class Action: Robbins LLP

SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities...

Aaron-dumas-jr , Nasdaq , Fulcrum-therapeutics-inc , Drug-administration , Fulcrum-therapeutics , Aaron-dumas , Case-about , Misled-investors-regarding , Lead-product-candidate , Investigational-new-drug , Clinical-hold-letter

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq

CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Cambridge , Cambridgeshire , United-kingdom , Dee-smith , Nasdaq , Fulcrum-therapeutics-inc , Drug-administration , Corporate-communications , Stock-incentive-plan , Fulcrum-therapeutics , Nasdaq-listing-rule , Nasdaq-fulc

ROSEN, A LEADING NATIONAL FIRM, Encourages Fulcrum

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum...

New-york , United-states , China , Chinese , Phillip-kim , Laurence-rosen , Rosen-law-firm , Facebook , Linkedin , Twitter , Drug-administration , Nasdaq

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Fulcrum

NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum...

China , New-york , United-states , Chinese , Phillip-kim , Laurence-rosen , Nasdaq , Facebook , Chinese-company , Twitter , Rosen-law-firm , Fulcrum-therapeutics-inc

Fulcrum Therapeutics, Inc. (FULC) Equity Alert: Contact

SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities...

Aaron-dumas-jr , Nasdaq , Drug-administration , Fulcrum-therapeutics-inc , Fulcrum-therapeutics , Aaron-dumas , Case-about , Misled-investors-regarding , Lead-product-candidate , Investigational-new-drug , Clinical-hold-letter